Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31168138 | 1.00 | HIF1A (0.58) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL31614995 | 1.00 | HIF1A (0.58) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Decyltriphenylphosphonium SCHEMBL29772910 | 1.00 | HIF1A (0.58) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL2446607 | 0.98 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL164301 | 0.98 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL5085298 | 0.98 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Water SCHEMBL3417999 | 0.98 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL5084888 | 0.98 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL7759526 | 0.98 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL8775234 | 0.98 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270648-A1 | MOLECULAR SIGNATURE FOR ASSESSING THE RESPONSIVENESS OF CANCER TO MITOCHONDRIA-TARGETED ANTIOXIDANTS | Université Catholique de Louvain (BE) | 2025-08-28 | — | — | US | claimed |
| EP-4341442-A1 | MOLECULAR SIGNATURE FOR ASSESSING THE RESPONSIVENESS OF CANCER TO MITOCHONDRIA-TARGETED ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2024-03-27 | — | — | EP | claimed |
| EP-4139484-A1 | THERAPEUTIC METHODS FOR PREVENTING TUMOR METASTASIS AND TUMOR RECURRENCE | Lunella Biotech, Inc. (CA) | 2023-03-01 | — | — | EP | claimed |
| US-20220389067-A1 | Methods of Treating Neurodegenerative Diseases Caused by G4C2 Expansion in C9ORF72 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-08 | — | — | US | claimed |
| WO-2022243541-A1 | MOLECULAR SIGNATURE FOR ASSESSING THE RESPONSIVENESS OF CANCER TO MITOCHONDRIA-TARGETED ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2022-11-24 | — | — | WO | claimed |
| US-12635689-B2 | Antifungal compositions | UNIVERSITY OF EXETER (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20260130908-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260081034-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | EMERJA CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260081035-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | EMERJA CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-12544375-B2 | Small molecule therapeutic for parkinson's disease paired with a biomarker of therapeutic activity | THE BOARD OF TRUSTEES OF THE LELAND JUNIOR UNIVERSITY (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250270648-A1 | MOLECULAR SIGNATURE FOR ASSESSING THE RESPONSIVENESS OF CANCER TO MITOCHONDRIA-TARGETED ANTIOXIDANTS | Université Catholique de Louvain (BE) | 2025-08-28 | — | — | US | disclosed |
| WO-2024245951-A1 | COMBINATION OF SLC8A1 INHIBITOR AND MITOCHONDRIA-TARGETED ANTIOXIDANT FOR TREATING MELANOMA | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-12-05 | — | — | WO | disclosed |
| WO-2022243541-A1 | MOLECULAR SIGNATURE FOR ASSESSING THE RESPONSIVENESS OF CANCER TO MITOCHONDRIA-TARGETED ANTIOXIDANTS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2022-11-24 | — | — | WO | disclosed |
| US-20220334133-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-10-20 | — | — | US | disclosed |
| US-20220288071-A1 | A SMALL MOLECULE THERAPEUTIC FOR PARKINSON'S DISEASE PAIRED WITH A BIOMARKER OF THERAPEUTIC ACTIVITY | ATOMWISE, INC. | 2022-09-15 | — | — | US | disclosed |
| CN-114929242-A | Methods and compounds for modifying mitochondrial function | 小利兰·斯坦福大学托管委员会 | 2022-08-19 | — | — | CN | disclosed |
| EP-4025222-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | The Board of Trustees of the Leland Stanford Junior University (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220174950-A1 | Antifungal Compositions | UNIVERSITY OF EXETER (GB) | 2022-06-09 | — | — | US | disclosed |
| WO-2022047228-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | EMERJA CORPORATION (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3945818-A1 | ANTIFUNGAL COMPOSITIONS | University of Exeter (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220174950-A1 | Antifungal Compositions | ERG28, MAPRE2, MRPS22 | HIF1A 4290/4885TRAP1 3286/4885CHRNA7 4756/4885 |
| US-12635689-B2 | Antifungal compositions | ERG28, CASP2, SRMS | HIF1A 4522/4885TRAP1 3714/4885CHRNA7 4416/4885 |
| US-12544375-B2 | Small molecule therapeutic for parkinson's disease paired with a biomarker of therapeutic activity | PINK1, SNCA, AIFM1 | HIF1A 2244/4885TRAP1 50/4885CHRNA7 1294/4885 |
| US-20260130908-A1 | METHODS AND COMPOUNDS MODIFYING MITOCHONDRIAL FUNCTION | SHMT2, NLN, TFAM | HIF1A 3024/4885TRAP1 204/4885CHRNA7 1187/4885 |
| US-20260081035-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | PYGB, CRH, CRY1 | HIF1A 1737/4885TRAP1 3456/4885CHRNA7 327/4885 |
| US-20260081034-A1 | SYSTEMS AND METHODS FOR MEASURING, LEARNING, AND USING EMERGENT PROPERTIES OF COMPLEX ADAPTIVE SYSTEMS | CRH, HCRTR1, PER2 | HIF1A 1589/4885TRAP1 2149/4885CHRNA7 477/4885 |
| US-20220288071-A1 | A SMALL MOLECULE THERAPEUTIC FOR PARKINSON'S DISEASE PAIRED WITH A BIOMARKER OF THERAPEUTIC ACTIVITY | RHOT2, NLN, OPA1 | HIF1A 588/4885TRAP1 60/4885CHRNA7 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.